APGE
Apogee Therapeutics

409
Mkt Cap
$4.78B
Volume
957,541.00
52W High
$84.56
52W Low
$26.20
PE Ratio
-16.21
APGE Fundamentals
Price
$70.00
Prev Close
$69.09
Open
$68.23
50D MA
$73.12
Beta
0.00
Avg. Volume
1.14M
EPS (Annual)
-$3.30
P/B
8.69
Rev/Employee
$0.00
$1,991.46
Loading...
Loading...
News
all
press releases
JPMorgan Chase & Co. Purchases 417,161 Shares of Apogee Therapeutics Inc. $APGE
JPMorgan Chase & Co. grew its position in Apogee Therapeutics Inc. (NASDAQ:APGE - Free Report) by 57.9% during the 3rd quarter, according to the company in its most recent disclosure with the...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million
Key PointsGreat Point Partners increased its APGE position by 70,000 shares in the fourth quarter; the estimated transaction value was $4.41 million based on quarterly average prices...
Nasdaq News: Markets·4d ago
News Placeholder
Apogee Therapeutics (APGE) Expected to Announce Earnings on Monday
Apogee Therapeutics (NASDAQ:APGE) will be releasing its Q4 2025 earnings before the market opens on Monday, March 2. (View Earnings Report at...
MarketBeat·7d ago
News Placeholder
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction
Key PointsPerceptive Advisors increased its Apogee Therapeutics position by 978,662 shares; the estimated trade value was $61.64 million (based on quarterly average prices...
Nasdaq News: Markets·7d ago
News Placeholder
Aberdeen Group plc Takes Position in Apogee Therapeutics Inc. $APGE
Aberdeen Group plc bought a new position in Apogee Therapeutics Inc. (NASDAQ:APGE - Free Report) during the third quarter, according to the company in its most recent filing with the SEC. The firm...
MarketBeat·8d ago
News Placeholder
Apogee Therapeutics Inc. (NASDAQ:APGE) Given Average Rating of "Moderate Buy" by Brokerages
Apogee Therapeutics Inc. (NASDAQ:APGE - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the fifteen brokerages that are currently covering the firm, MarketBeat reports...
MarketBeat·9d ago
News Placeholder
Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors DelveInsight
Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with...
PR Newswire·13d ago
News Placeholder
Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million
Key PointsAffinity Asset Advisors bought 61,500 shares of Apogee Therapeutics in the fourth quarter; the estimated transaction value was $3.87 million (based on quarterly average prices...
Nasdaq News: Markets·15d ago
News Placeholder
Michael Thomas Henderson Sells 20,000 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock
Apogee Therapeutics Inc. (NASDAQ:APGE - Get Free Report) CEO Michael Thomas Henderson sold 20,000 shares of the business's stock in a transaction on Wednesday, February 11th. The stock was sold at an...
MarketBeat·16d ago
News Placeholder
Apogee Therapeutics touts quarterly-to-biannual AD dosing shift, expands asthma ambitions at conference
Executives from Apogee Therapeutics (NASDAQ:APGE) outlined their development and commercialization priorities at Guggenheim's Emerging Outlook Biotech Conference, emphasizing plans to shift treatment...
MarketBeat·17d ago
<
1
2
...
>

Latest APGE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.